JP2018083761A5 - - Google Patents

Download PDF

Info

Publication number
JP2018083761A5
JP2018083761A5 JP2016225825A JP2016225825A JP2018083761A5 JP 2018083761 A5 JP2018083761 A5 JP 2018083761A5 JP 2016225825 A JP2016225825 A JP 2016225825A JP 2016225825 A JP2016225825 A JP 2016225825A JP 2018083761 A5 JP2018083761 A5 JP 2018083761A5
Authority
JP
Japan
Prior art keywords
lipoteichoic acid
muscle degradation
suppressing
degradation
suppressing muscle
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016225825A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018083761A (ja
JP6762855B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority to JP2016225825A priority Critical patent/JP6762855B2/ja
Priority claimed from JP2016225825A external-priority patent/JP6762855B2/ja
Publication of JP2018083761A publication Critical patent/JP2018083761A/ja
Publication of JP2018083761A5 publication Critical patent/JP2018083761A5/ja
Application granted granted Critical
Publication of JP6762855B2 publication Critical patent/JP6762855B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016225825A 2016-11-21 2016-11-21 筋肉の分解抑制剤 Active JP6762855B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2016225825A JP6762855B2 (ja) 2016-11-21 2016-11-21 筋肉の分解抑制剤

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2016225825A JP6762855B2 (ja) 2016-11-21 2016-11-21 筋肉の分解抑制剤

Publications (3)

Publication Number Publication Date
JP2018083761A JP2018083761A (ja) 2018-05-31
JP2018083761A5 true JP2018083761A5 (https=) 2020-01-23
JP6762855B2 JP6762855B2 (ja) 2020-09-30

Family

ID=62236962

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016225825A Active JP6762855B2 (ja) 2016-11-21 2016-11-21 筋肉の分解抑制剤

Country Status (1)

Country Link
JP (1) JP6762855B2 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7488182B2 (ja) * 2018-06-01 2024-05-21 雪印メグミルク株式会社 筋修復促進用組成物
JP7691937B2 (ja) * 2020-01-10 2025-06-12 株式会社ヤクルト本社 乳酸菌細胞壁破砕物及び乳酸菌細胞壁破砕物の製造方法
WO2022039215A1 (ja) * 2020-08-21 2022-02-24 アサヒグループホールディングス株式会社 筋肉の分解抑制剤
JPWO2022215568A1 (https=) * 2021-04-08 2022-10-13

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6339526B2 (ja) * 2015-05-22 2018-06-06 アサヒグループホールディングス株式会社 筋肉の分解抑制剤

Similar Documents

Publication Publication Date Title
WO2014121302A3 (en) Compositions and methods
JP2018083761A5 (https=)
PL4031157T3 (pl) Szczepy bakteryjne, ich kompozycje i ich zastosowanie w leczeniu zaburzeń żołądkowo-jelitowych
MX354047B (es) Cepas/celulas de lactobacillus secadas por aspersion, y el uso de las mismas contra helicobacter pylori.
CL2012002062A1 (es) Composicion que comprende lactobacillus plantarum y pediococcus acidilactici o mutantes o variantes de las mismas; producto farmaceutico, veterinario y comestible que comprende dicha composicion; cepa de lactobacillus plantarum; cepa de pediococcus acidilactici.
IL260955A (en) A mini tablet for oral administration containing sacubitril and valsartan for the treatment of heart failure
MY187060A (en) Bifidobacteria as probiotic foundation species of gut microbiota
WO2016106343A8 (en) Probiotic organisms for diagnosis, monitoring, and treatment of inflammatory bowel disease
CN107405369A8 (zh) 包含细菌的组合物及将其用于治疗和/或预防胃肠道疾病、代谢疾病和/或其它疾病的方法
MY191961A (en) Nutritional composition for gastrointestinal environment to provide improved microbiome and metabolic profile
PT3277295T (pt) Composição para o tratamento de um estado metabólico patogénico da flora intestinal e de doenças derivadas
HK1259441A1 (zh) 包含btk抑制剂的制剂/组合物
MX383749B (es) Cepas probioticas con capacidad de absorber colesterol, métodos y usos de las mismas
WO2015179823A8 (en) Lung localized inhibitors of alpha(v)beta 6
EP3255140A4 (en) Lactic acid bacteria, natural immunoactivator and infection preventative/therapeutic derived from said lactic acid bacteria, and food/beverage
MY183171A (en) Composition containing bacterium belonging to genus lactobacillus
WO2016074641A8 (zh) Nadh或其盐在制备治疗苯丙酮尿症药物或保健品的应用
EA201891343A1 (ru) Новый кластер генов eps текстурирующих молочнокислых бактерий
WO2017123610A3 (en) Bacteria engineered to detoxify deleterious molecules
DK3254693T3 (da) Mælkesyrebakterieindeholdende sammensætning, oral farmaceutisk sammensætning til at behandle hpv-infektion og/eller hpv-associerede tumorer og slimhindeimmunitietsinducerende middel
JP2016056119A5 (https=)
EP4470625A3 (en) A pharmaceutical composition comprising a combination of probiotic and prebiotic to treat stunting
MY174136A (en) Bacterium belonging to genus lactobacillus
JP2016003187A5 (https=)
HUE043451T2 (hu) Lactobacillus rhamnosus baktérium például bakteriális vaginosis kezelésére